Industry news
- Industry news
- Development
- News
Orphagen Pharmaceuticals Awarded Phase 2 SBIR Funding to Investigate Novel Drug Class for CNS Disorders
In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.
Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Company details
If you want to find out more about the company visit Orphagen Pharmaceuticals profile.
Related reports
Related news
Latest News
- OXIS International, Inc. (OXIS) Announces the Launch of Oxis Consumer Products Subsidiary
- From Oranienburg to the rest of the world: global market launch of Daxas
- Straumann launches new CADCAM dental restoration system
- Neuronetics selected by World Economic Forum as 2011 Technology Pioneer
- QRxPharma to Sponsor Symposium at International Association for the Study of Pain Meetings
- Bayer
- PharmaNet Joins Medidata Solutions' CRO Partner Program
- Randomized Controlled Trial Finds Masimo PVI Improves Fluid Management During Surgery
- Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
- Prometheus Launches the First Serogenetic Test to Predict Risk of Complications from Crohn's Disease
- More news... | RSS Feed...
Most Viewed
OXIS International, Inc. (OXIS) Announces the Launch of Oxis Consumer Products Subsidiary
From Oranienburg to the rest of the world: global market launch of Daxas
Publication of Phase II trial results of NGR-hTNF in liver cancer by the British Journal of Cancer
Straumann launches new CADCAM dental restoration system
Neuronetics selected by World Economic Forum as 2011 Technology Pioneer
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us